CY1123084T1 - Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι - Google Patents

Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Info

Publication number
CY1123084T1
CY1123084T1 CY20201100587T CY201100587T CY1123084T1 CY 1123084 T1 CY1123084 T1 CY 1123084T1 CY 20201100587 T CY20201100587 T CY 20201100587T CY 201100587 T CY201100587 T CY 201100587T CY 1123084 T1 CY1123084 T1 CY 1123084T1
Authority
CY
Cyprus
Prior art keywords
storage disease
disease type
treatment
glycogen storage
glycogen
Prior art date
Application number
CY20201100587T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123084(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07001091.3A external-priority patent/EP1782825B1/en
Application filed by Duke University filed Critical Duke University
Publication of CY1123084T1 publication Critical patent/CY1123084T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Περιγράφονται μέθοδοι θεραπείας της ασθένειας αποθήκευσης γλυκογόνου τύπου ΙΙ, με τη χορήγηση όξινης α-γλυκοσιδάσης, όπως επίσης συνθέσεις για χρήση στη θεραπεία της ασθένειας αποθήκευσης γλυκογόνου τύπου II.
CY20201100587T 2000-07-18 2020-06-24 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι CY1123084T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii
EP16178390.7A EP3108895B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii
EP07001091.3A EP1782825B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage diseases type II
EP01951000A EP1301201B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii
EP14167882.1A EP2767291B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Publications (1)

Publication Number Publication Date
CY1123084T1 true CY1123084T1 (el) 2021-10-29

Family

ID=22818451

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101308T CY1120977T1 (el) 2000-07-18 2018-12-07 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
CY20201100587T CY1123084T1 (el) 2000-07-18 2020-06-24 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY181101308T CY1120977T1 (el) 2000-07-18 2018-12-07 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Country Status (18)

Country Link
US (10) US7056712B2 (el)
EP (4) EP3449934B1 (el)
JP (10) JP5113312B2 (el)
AT (1) ATE355075T1 (el)
AU (3) AU7194101A (el)
BR (1) BR0113006A (el)
CA (1) CA2416492C (el)
CY (2) CY1120977T1 (el)
DE (1) DE60126947T2 (el)
DK (5) DK1301201T3 (el)
ES (5) ES2523024T3 (el)
HK (3) HK1054690A1 (el)
LT (3) LT3449934T (el)
MX (1) MXPA03000474A (el)
PT (5) PT3108895T (el)
SI (3) SI3108895T1 (el)
TW (1) TWI280882B (el)
WO (1) WO2002005841A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3449934B1 (en) * 2000-07-18 2020-05-20 Duke University Treatment of glycogen storage disease type ii
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) * 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2006002283A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
ES2371913T3 (es) * 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
ES2830350T3 (es) 2008-05-07 2021-06-03 Biomarin Pharm Inc Péptidos de dirección lisosómica y usos de los mismos
WO2010005565A2 (en) * 2008-07-08 2010-01-14 Duke University Method of treating glycogen storage disease
ES2569514T3 (es) * 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
EP2981551B1 (en) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Methods and compositions for treatment of pompe disease
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
EA038986B1 (ru) 2014-09-30 2021-11-18 Амикус Терапьютикс, Инк. Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов
EP3292871B1 (en) 2015-05-07 2021-06-23 The University of Tokyo Nanoreactor using polyion complex polymersomes, and method for producing same
EP3344337A4 (en) * 2015-08-31 2019-03-06 Duke University METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
EA201891507A1 (ru) 2015-12-30 2018-12-28 Амикус Терапьютикс, Инк. Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
WO2017173060A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
IL295551A (en) 2016-03-30 2022-10-01 Amicus Therapeutics Inc A method for selecting recombinant proteins with a high amount of mannose-6-phosphate
KR20230125339A (ko) 2016-04-15 2023-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
BR112020005249A2 (pt) 2017-09-22 2020-09-24 The Trustees Of The University Of Pennsylvania terapia de gene para tratar mucopolissacaridose tipo ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AU4072499A (en) 1998-05-13 1999-11-29 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
ES2312222T3 (es) * 1998-12-07 2009-02-16 Genzyme Corporation Tratamiento de la enfermedad de pompe.
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
EP3449934B1 (en) * 2000-07-18 2020-05-20 Duke University Treatment of glycogen storage disease type ii
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
DK1782825T3 (da) 2014-11-03
DK2767291T3 (en) 2016-12-05
LT2767291T (lt) 2016-11-25
LT3108895T (lt) 2018-11-26
US20100254966A1 (en) 2010-10-07
US8900552B2 (en) 2014-12-02
ES2700865T3 (es) 2019-02-19
JP2020019822A (ja) 2020-02-06
AU2010200487A1 (en) 2010-03-04
US20150004152A1 (en) 2015-01-01
EP2767291A2 (en) 2014-08-20
HK1103363A1 (en) 2007-12-21
EP3108895B1 (en) 2018-09-19
TWI280882B (en) 2007-05-11
DK3108895T3 (en) 2018-11-26
AU7194101A (en) 2002-01-30
JP2018199721A (ja) 2018-12-20
US20180185457A1 (en) 2018-07-05
LT3449934T (lt) 2020-08-10
CA2416492A1 (en) 2002-01-24
JP5113312B2 (ja) 2013-01-09
US20050123531A1 (en) 2005-06-09
SI3449934T1 (sl) 2020-09-30
JP2013231081A (ja) 2013-11-14
CA2416492C (en) 2008-04-29
PT2767291T (pt) 2016-10-25
EP2767291B1 (en) 2016-09-14
US20020110551A1 (en) 2002-08-15
AU2001271941B2 (en) 2007-03-01
BR0113006A (pt) 2004-10-19
CY1120977T1 (el) 2019-12-11
PT3108895T (pt) 2018-12-18
US7056712B2 (en) 2006-06-06
DK1301201T3 (da) 2007-04-02
JP2004503598A (ja) 2004-02-05
JP2018002749A (ja) 2018-01-11
DE60126947D1 (de) 2007-04-12
HK1054690A1 (en) 2003-12-12
JP2016056206A (ja) 2016-04-21
PT3449934T (pt) 2020-06-25
US20210169996A1 (en) 2021-06-10
US20160184410A1 (en) 2016-06-30
US20080175833A1 (en) 2008-07-24
SI2767291T1 (sl) 2016-11-30
DK3449934T3 (da) 2020-06-29
EP2767291A3 (en) 2014-10-08
MXPA03000474A (es) 2003-10-06
JP6163216B2 (ja) 2017-07-12
WO2002005841A1 (en) 2002-01-24
EP1301201A1 (en) 2003-04-16
US9370556B2 (en) 2016-06-21
JP2017137357A (ja) 2017-08-10
ES2799882T3 (es) 2020-12-22
ES2523024T3 (es) 2014-11-20
EP3108895A1 (en) 2016-12-28
US20120058132A1 (en) 2012-03-08
US9907839B2 (en) 2018-03-06
ATE355075T1 (de) 2006-03-15
JP2012006953A (ja) 2012-01-12
EP1301201B1 (en) 2007-02-28
US10792341B2 (en) 2020-10-06
JP5792774B2 (ja) 2015-10-14
PT1301201E (pt) 2007-03-30
JP2014185187A (ja) 2014-10-02
EP3449934A1 (en) 2019-03-06
US20130195834A1 (en) 2013-08-01
ES2599401T3 (es) 2017-02-01
SI3108895T1 (sl) 2019-01-31
EP3449934B1 (en) 2020-05-20
DE60126947T2 (de) 2007-10-31
ES2277931T3 (es) 2007-08-01
HK1197656A1 (zh) 2015-02-06
JP2008081507A (ja) 2008-04-10
PT1782825E (pt) 2014-11-04

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
DK1294379T3 (da) En hidtil ukendt anvendelse af deferipron
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
SE0100873D0 (sv) Method of treatment
EP1782825A3 (en) Treatment of glycogen storage diseases type II
DE60336504D1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel